Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
“Because medicine abhors a therapeutic vacuum,” the hallucinogens psilocybin and LSD are being revisited as potential candidates for treating depression. But effect size seems less than that of currently approved antidepressants.
Neurology November 14th 2022
In this phase 2 double-blind trial, adults with treatment-resistant depression were randomly assigned to receive psychological support and a single dose of a proprietary, synthetic form of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control). The Montgomery-Sberg Depression Rating Scale (MADRS) total score change from baseline to week three was the main outcome measure. Secondary endpoints included remission at week 3, response at week 3, and sustained response at 12 weeks.
Psychiatry November 8th 2022
MDLinx
This article provides a brief review of three important books on the thinking and experience around psychedelics in medicine: The Promise of Psychedelics, by Peter Silverstone, MD; Psychedelic Medicine, by Richard Louis Miller, MA, PhD; How to Change Your Mind, by Michael Pollan.
Clinical Advisor
This overview and discussion highlights the learnings gleaned during practice in a ketamine service unit. Discussion points include treatment considerations for the two entities, switching from IV to intranasal, and a collection of pearls.
JAMA Network
In this meta-analysis including 340 patients across six clinical trials, ECT was more effective than ketamine in treating depression. There were no identified differences between the groups in terms of cognition, memory, or serious adverse events.
Neurology October 25th 2022
In this study involving 452 patients with diagnoses of MDD, GAD, and PTSD, IM ketamine reduced depression by 38% and anxiety by 50%, with persistence over 7 months of maintenance therapy.
Family Medicine/General Practice October 20th 2022